Quote Overview

Stock Activity

Open	137.06
Day Low	134.12
Day High	137.21
52 Wk Low	96.80
52 Wk High	151.58
Avg. Volume	1,307,440
Market Cap	40.29 B
Dividend	0.94 ( 0.69%)
Beta	1.11

Key Earnings Data

Earnings ESP	0.72%
Most Accurate Est	1.20
Current Qtr Est	1.19
Current Yr Est	5.50
Exp Earnings Date	5/28/24
Prior Year EPS	5.44
Exp EPS Growth (3-5yr) 6.00%
Forward PE	24.99
PEG Ratio	4.17

Computer and Technology » Electronics - Testing Equipment

Research Reports for A

All Zacks’ Analyst Reports

Premium Research for A

Style Scores D Value B Growth C Momentum C VGM
Zacks Rank	Hold 3
Zacks Industry Rank	Top 4%(9 out of 252)
Zacks Sector Rank	Top 31% (5 out of 16)
Earnings ESP	0.72%
Research Reports for A Analyst \| Snapshot

( = Change in last 30 days)

View All Zacks Rank #1 Strong Buys

Premium Research: Industry Analysis

Top Peers	Symbol	Zacks Rank
Agilent Technologies	A
AMETEK	AME
Fortive	FTV
Itron	ITRI
Teradyne	TER
Cognex	CGNX
COREwafer Industries	AHIX	NA

See all Electronics - Testing Equipment Peers

Zacks News for A

No Record found.

Company Summary

Santa Clara, CA-based Agilent Technologies, Inc. was originally a spin-off from Hewlett-Packard. The company is an original equipment manufacturer (OEM) of a broad-based portfolio of test and measurement products serving multiple end markets.

Over the last three years, the company has diversified into new end markets, namely industrial, chemical and electronics markets. The company has three business segments, including Life Sciences & Applied Markets Group (LSAG), Diagnostics and Genomics Group (DGG) and Agilent Cross Lab Group (ACG).

The company uses a direct sales model for the distribution of its products, which is supplemented by distributors, resellers, manufacturers’ representatives, telesales and electronic commerce, as necessary.

Agilent reported revenues of $6.83 billion in fiscal 2023 which remained flat year over year. The company generated 40% of revenues from Americas, 26% from Europe and 34% from Asia-Pacific region in the fiscal 2023.

LSAG accounted for 56% of fiscal 2023 revenues (down 4% from fiscal 2022), DGG contributed 21% (which increased 1% from fiscal 2022) and ACG represented the remaining 23% (improving 8% from fiscal 2022).

Most of the competition for these three segments comes from Bruker Corp., Danaher Corp, Affymetrix, GE Healthcare, Life Technologies Corp., Thermo Fisher Scientific, Waters Corp., Illumina, Inc., Life Technologies Corp., Abbott Laboratories, Sakura, Roche, Perkin Elmer Corp., Shimadzu Corp, Heidenhain Corp., Malvern Instruments, Seiko Instruments, Veeco Instruments and Zygo Corp.